OncoZenge Q4: Partnerships in place - Redeye

Redeye provides a research update following the Q4 report published by OncoZenge earlier today. The company manages to maintain a low OPEX and cash burn as the primary focus has been business development initiatives. With a new strategic partnership with Molteni Farmaceutici and a financing agreement with Yangtian Pharma, the company is now back on track with the upcoming phase III study in sight.

Länk till analysen i sin helhet: https://www.redeye.se/research/1081837/oncozenge-q4-partnerships-in-place?utm_source=finwire&utm_medium=RSS